BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...hired Craig Taylor as head of business operations; he was director of business development at Virion...
BioCentury | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

...to confer protection. X-Vax believes the key to immunity against HSV is to prevent new virion...
BioCentury | May 22, 2019
Preclinical News

SR-Tiget-led team boosts ‘don’t eat me’ signals on viral vectors to improve efficacy

Boosting surface levels of a "don't eat me" signal on lentiviral vectors could enable administration of lower gene therapy doses and prevent immune responses by shielding the vectors from phagocytosis. HIV-derived lentiviral gene therapy vectors...
BioCentury | Dec 20, 2018
Company News

Management tracks: Evox names Moses chairman; Kapeller joins GV

...Moses as chairman. This month, the former Ablynx N.V. CEO was also appointed chairman of Virion...
BioCentury | Dec 17, 2018
Company News

Management tracks: Vertex’s Graney joins Generation Bio

...Squibb Co. (NYSE:BMY) VP Louisa Salter-Cid as CSO in September (see "Gossamer's War Chest" ). Virion...
...at Insmed Inc. (NASDAQ:INSM). BC Staff Acadia Pharmaceuticals Inc. Generation Bio Co. Gossamer Bio Inc. Merck & Co. Inc. Vertex Pharmaceuticals Inc. Virion...
BioCentury | Nov 16, 2018
Emerging Company Profile

Virion: Harnessing viral defects

...Vanessa King, citing an increase in strains resistant to marketed treatments for influenza and RSV. Virion’s...
...of resistance would require simultaneous mutations in both the defective interfering virus and pathogenic virus. Virion...
...Warwick, Coventry, U.K. Virion Biotherapeutics Ltd., London, U.K. Mary Romeo, Staff Writer Abingworth University of Warwick Respiratory syncytial virus (RSV) Virion...
BioCentury | Sep 17, 2018
Company News

Management tracks: Ultragenyx, Epizyme

...and said COO Matthew Ros will become chief strategy and business officer. Respiratory virus company Virion...
...president and CEO and Isabel Najera as CSO. King is a venture partner at Abingworth, Virion's...
...cancer company Ignyta Inc., which Roche acquired. Jaime De Leon GlaxoSmithKline plc Ignyta Inc. Oric Pharmaceuticals Inc. Roche Tiaki Therapeutics Ultragenyx Pharmaceutical Inc. Virion...
BioCentury | Dec 22, 2017
Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
Items per page:
1 - 10 of 92
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...hired Craig Taylor as head of business operations; he was director of business development at Virion...
BioCentury | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

...to confer protection. X-Vax believes the key to immunity against HSV is to prevent new virion...
BioCentury | May 22, 2019
Preclinical News

SR-Tiget-led team boosts ‘don’t eat me’ signals on viral vectors to improve efficacy

Boosting surface levels of a "don't eat me" signal on lentiviral vectors could enable administration of lower gene therapy doses and prevent immune responses by shielding the vectors from phagocytosis. HIV-derived lentiviral gene therapy vectors...
BioCentury | Dec 20, 2018
Company News

Management tracks: Evox names Moses chairman; Kapeller joins GV

...Moses as chairman. This month, the former Ablynx N.V. CEO was also appointed chairman of Virion...
BioCentury | Dec 17, 2018
Company News

Management tracks: Vertex’s Graney joins Generation Bio

...Squibb Co. (NYSE:BMY) VP Louisa Salter-Cid as CSO in September (see "Gossamer's War Chest" ). Virion...
...at Insmed Inc. (NASDAQ:INSM). BC Staff Acadia Pharmaceuticals Inc. Generation Bio Co. Gossamer Bio Inc. Merck & Co. Inc. Vertex Pharmaceuticals Inc. Virion...
BioCentury | Nov 16, 2018
Emerging Company Profile

Virion: Harnessing viral defects

...Vanessa King, citing an increase in strains resistant to marketed treatments for influenza and RSV. Virion’s...
...of resistance would require simultaneous mutations in both the defective interfering virus and pathogenic virus. Virion...
...Warwick, Coventry, U.K. Virion Biotherapeutics Ltd., London, U.K. Mary Romeo, Staff Writer Abingworth University of Warwick Respiratory syncytial virus (RSV) Virion...
BioCentury | Sep 17, 2018
Company News

Management tracks: Ultragenyx, Epizyme

...and said COO Matthew Ros will become chief strategy and business officer. Respiratory virus company Virion...
...president and CEO and Isabel Najera as CSO. King is a venture partner at Abingworth, Virion's...
...cancer company Ignyta Inc., which Roche acquired. Jaime De Leon GlaxoSmithKline plc Ignyta Inc. Oric Pharmaceuticals Inc. Roche Tiaki Therapeutics Ultragenyx Pharmaceutical Inc. Virion...
BioCentury | Dec 22, 2017
Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
Items per page:
1 - 10 of 92